Early Dose-Escalation Data for Potential Treatment for Chronic Lymphocytic Leukemia Released
According to a story from BioPortfolio, the global biopharmaceutical company Celgene Corporation recently announced the release of early data from the dose-escalation portion of a Phase 1/2 clinical trial of lisocabtagene…